Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company offers generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparat… Read more
Antibiotice Ia (ATB) - Total Assets
Latest total assets as of September 2025: RON1.40 Billion RON
Based on the latest financial reports, Antibiotice Ia (ATB) holds total assets worth RON1.40 Billion RON as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Antibiotice Ia - Total Assets Trend (2020–2024)
This chart illustrates how Antibiotice Ia’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Antibiotice Ia - Asset Composition Analysis
Current Asset Composition (September 2024)
Antibiotice Ia's total assets of RON1.40 Billion consist of 37.1% current assets and 62.9% non-current assets.
| Asset Category | Amount (RON) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RON0.00 | 0.2% |
| Accounts Receivable | RON320.05 Million | 25.0% |
| Inventory | RON169.86 Million | 13.3% |
| Property, Plant & Equipment | RON0.00 | 0.0% |
| Intangible Assets | RON55.17 Million | 4.3% |
| Goodwill | RON0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Antibiotice Ia's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Antibiotice Ia's current assets represent 37.1% of total assets in 2024, a decrease from 43.5% in 2020.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2024, down from 0.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 25.0% of total assets.
Antibiotice Ia Competitors by Total Assets
Key competitors of Antibiotice Ia based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Antibiotice Ia - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Antibiotice Ia generates 0.53x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Antibiotice Ia generates $7.99 in net profit.
Antibiotice Ia - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 2.25 | 2.16 |
| Quick Ratio | 1.47 | 1.48 | 1.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RON323.09 Million | RON 256.58 Million | RON 201.72 Million |
Antibiotice Ia - Advanced Valuation Insights
This section examines the relationship between Antibiotice Ia's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.47 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 12.3% |
| Total Assets | RON1.28 Billion |
| Market Capitalization | $94.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Antibiotice Ia's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Antibiotice Ia's assets grew by 12.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Antibiotice Ia (2020–2024)
The table below shows the annual total assets of Antibiotice Ia from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | RON1.28 Billion | +12.30% |
| 2023-09-30 | RON1.14 Billion | +33.01% |
| 2022-09-30 | RON856.47 Million | -4.35% |
| 2021-09-30 | RON895.39 Million | +3.75% |
| 2020-09-30 | RON863.00 Million | -- |